Previous 10 | Next 10 |
Clinical trial will utilize a single-protocol Phase 1/2/3 design UX701 manufacturing complete at commercial quality and scale using HeLa PCL technology First patient to be dosed in the first half of 2021 NOVATO, Calif., Jan. 21, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Ph...
The February 6, 2020 Emerald Groundhog Day Investment Forum began with a special presentation from Emerald’s CEO and Life Sciences research directors discussing the new COVID-19 virus that was beginning to emerge in the western world. One year later, the pervasive pandemic will m...
Ultragenyx Pharmaceutical ([[RARE]] -5.6%) said 2021 Crysvita revenue in the Ultragenyx territories is expected to be between $180M-$190M, with fiscal year 2020 sales in the range of $137M-$139M.Year-end 2020 cash balance seen at about $1.2B.As announced last week, Phase 3 DTX401 study f...
Preliminary 2020 Crysvita revenue in Ultragenyx Territories of $137 million to $139 million 2021 Crysvita Ultragenyx revenue expected in the range of $180 million to $190 million Year-end 2020 cash balance of approximately $1.2 billion NOVATO, Calif., Jan. 11, 2021...
Ultragenyx Pharmaceutical ([[RARE]] +2.3%) has announced longer-term safety and efficacy data from the first three cohorts of the ongoing Phase 1/2 studies of DTX401 for Glycogen Storage Disease Type Ia (GSDIa), and DTX301 ornithine transcarbamylase ((OTC)) deficiency. In addition, dosin...
Durable and Clinically Meaningful Responses Reported from Phase 1/2 Studies of DTX401 for GSDIa and DTX301 for OTC Phase 3 Studies for DTX401 and DTX301 to Begin in 2021 IND for UX701 for Wilson Disease Submitted; Expect to Enter Clinic in First Half 2021 using AAV Drug ...
NOVATO, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's Chief E...
The recent acquisition of rare dug heavyweight Alexion Pharmaceuticals signals a willingness of big pharma to enter the field. Typically, big pharma was interested in larger patient populations however the lack of commercial ready products has broaden their focus. With interest ra...
Mereo BioPharma (MREO) jumps 18% after hours, after announcing a license and collaboration agreement with Ultragenyx Pharmaceutical (RARE) for setrusumab, a monoclonal antibody, for osteogenesis imperfecta ((OI)), a rare genetic disorder characterized by fr...
Clinical-stage monoclonal antibody in development for rare genetic bone disease that builds on Ultragenyx’s existing bone franchise Ultragenyx leads and funds development to approval; Mereo retains commercial rights in Europe, Ultragenyx commercializes in US and in rest o...
News, Short Squeeze, Breakout and More Instantly...
Ultragenyx Pharmaceutical Inc. Company Name:
RARE Stock Symbol:
NASDAQ Market:
Ultragenyx Pharmaceutical Inc. Website:
NOVATO, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultrarare genetic diseases, today announced that it will host a conference call at 5...
NOVATO, Calif., July 24, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the company will share the latest clinical data, regulatory progress and program next steps for GTX-102, its investigational antisense oligonucleotide for Angelman syndrome, on Wed...
2024-07-24 04:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...